# 2026-19282: FDA Asks: Should States Skip Federal Health Rules?

2026-19282, Agency Information Collection Activities; Proposed Collection; Comment Request; State Petitions for Exemption From Preemption, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-21, effective 2026-11-20 (as of 2026-09-28).

- Canonical: https://policyrisk.com/federal-register/2026-19282
- As of: 2026-09-28
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19282
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; State Petitions for Exemption From Preemption
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 59781
- Published: 2026-09-21
- Effective: 2026-11-20
- Comments close: 2026-11-20
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-09-28

## In one line

FDA Asks: Should States Skip Federal Health Rules?

## Summary

The FDA wants your thoughts on how states ask for permission to skip certain federal rules about health products. This affects state governments and could change how they report info to the FDA. You’ve got until November 20, 2026, to share your comments—no cost involved, just your voice!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of our reporting requirements contained in FDA regulations governing state petitions for exemption from preemption.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-19282 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/21/2026-19282/agency-information-collection-activities-proposed-collection-comment-request-state-petitions-for)
- [2026-19282 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-21/pdf/2026-19282.pdf)

## Related
- [Previous: 2026-19281, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-19281)
- [Next: 2026-19283, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-19283)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19282 (as of 2026-09-28).